RDY 56.57 Dr. Reddy's Laboratories Ltd $RDY Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
RDY 56.57 Dr. Reddy's Laboratories Ltd $RDY Hit a 52 week high of 56.82 Closing the day 09:44 at 56.57 +0.12 +0.21% With a day low of 56.40 and a total volume of 13,958.

RDY Recent Posts: http://investorshangout.com/Dr-Reddys-Laborat...RDY-52499/

RDY Dr. Reddy's Laboratories Ltd Recent Headline News

Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST

ENDP: 67.58 (-0.31), RDY: 56.48 (+0.03)

Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 87.13 (-5.86), ACT: 241.51 (+0.89), MYL: 55.42 (+1.62), RDY: 56.48 (+0.03)

Dr. Reddy's Laboratories (RDY) Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 12:50AM CDT

RDY: 56.48 (+0.03)

Dr. Reddys ups revenues 7% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:43PM CDT

RDY: 56.48 (+0.03)

Dr. Reddy's FQ2 EPS of $0.54
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 5:55AM CDT

RDY: 56.48 (+0.03)

Dr. Reddy's Q2 and H1 FY15 Financial Results
Business Wire - Wed Oct 29, 5:41AM CDT
--Q2 FY15 EBITDA at Rs. 8.7 billion (24% of the revenues)
RDY: 56.48 (+0.03)

Dr. Reddy's Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Business Wire - Tue Oct 28, 12:24PM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE(R) (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
RDY: 56.48 (+0.03)

Dr. Reddy's reports on October 29
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 6:09AM CDT

RDY: 56.48 (+0.03)

Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014
Business Wire - Fri Oct 17, 4:38AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 56.48 (+0.03)

Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 49.21 (-0.52), SCMP: 11.40 (+0.98), RDY: 56.48 (+0.03)

Dr Reddys Laboratories Has Returned 20.3% Since SmarTrend Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 08, 4:57PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 20.35% as of today's recent price of $49.92.
RDY: 56.48 (+0.03)

Dr Reddys Laboratories Shares Up 26.0% Since SmarTrend's Buy Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 01, 11:03AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 25.96% as of today's recent price of $52.25.
RDY: 56.48 (+0.03)

Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:19PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) has launched its generic version of Sunovion Pharmaceuticals Inc.???s Xopenex in the U.S.
SUPN: 8.53 (+0.13), MYL: 55.42 (+1.62), TEVA: 57.71 (-0.73), RDY: 56.48 (+0.03)

Uptrend Call Working As Dr Reddys Laboratories Stock Rises 26.6% (RDY)
Comtex SmarTrend(R) - Wed Sep 24, 9:40AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 26.59% as of today's recent price of $52.51.
RDY: 56.48 (+0.03)

Dr. Reddy's unveils US FDA approved Levalbuterol Inhalation Solution, USP for oral inhalation only
M2 - Wed Sep 24, 7:03AM CDT
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the market availability of Levalbuterol Inhalation Solution, USP 0.31 mg /3 ml, 0.63 mg /3 ml, 1.25 mg / 3 ml Unit-Dose Vials in the US.
RDY: 56.48 (+0.03)

Dr. Reddy's Announces the Launch of LEVALBUTEROL INHALATION SOLUTION, USP
Business Wire - Wed Sep 24, 2:27AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 56.48 (+0.03)

17.9% Return Seen to Date on SmarTrend Dr Reddys Laboratories Call (RDY)
Comtex SmarTrend(R) - Tue Sep 09, 4:52PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 17.91% as of today's recent price of $48.91.
RDY: 56.48 (+0.03)

Uptrend Call Working As Dr Reddys Laboratories Stock Rises 18.5% (RDY)
Comtex SmarTrend(R) - Tue Sep 02, 10:58AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 2 months, Dr Reddys Laboratories has returned 18.47% as of today's recent price of $49.14.
RDY: 56.48 (+0.03)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 7

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 5

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 0

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 3

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 3

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 4

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Unleashing Innovation: The WeStart Conference in Shanghai

Updated Category News Views 170

WeStart 2025 Conference Sparks Innovation in Shanghai Recently, the WeStart 2025 Entrepreneurial Investment Conference made headlines as it took center stage in an international dialogue around technological innovation and investment. This vibrant and engaging event unfolded as part of the esteemed Pujiang Innovation Forum, showcasing a bright future for entrepreneurs and...

Continue Reading
Celebrating Richard Green's Legacy at Mar-Jac Poultry

Updated Category News Views 128

Richard Green's Remarkable Retirement Journey at Mar-Jac Poultry Mar-Jac Poultry has officially announced the retirement of Richard Green, a prominent figure whose extensive service played a vital role in shaping the company's success. His retirement signifies the end of an era, marking 40 years filled with dedication, professionalism, and a sincere commitment to Mar-Jac....

Continue Reading
Saudi Arabia's Tech Revolution: Insights from Daniel Nikic

Updated Category News Views 179

Saudi Arabia's Vision for Technological Transformation Daniel Nikic, a prominent figure in AI investment and founder of an investment research firm, has brought back significant insights from a key conference focused on combating desertification. His analysis reveals ambitious plans related to technology integration in a growing economy, particularly in sectors poised for...

Continue Reading
IPG Photonics Earnings Preview: What Investors Should Know

Updated Category News Views 207

Overview of IPG Photonics and Upcoming Earnings IPG Photonics (NASDAQ: IPGP) is preparing to release its quarterly earnings report soon, creating significant interest among investors. With expectations high, many are keen to learn whether the company will meet or exceed analysts' estimates, particularly regarding earnings per share (EPS). Analysts project that IPG...

Continue Reading
Exciting Partnership Between Jollibee and KATSEYE Unveiled

Updated Category News Views 533

Jollibee Teams Up with KATSEYE for a Unique Experience In a vibrant celebration of joy and community, Jollibee is thrilled to announce its partnership with the international girl group, KATSEYE. This collaboration is set to create delightful connections with fans in North America, introducing them to exciting new experiences and exclusive merchandise. Bringing Fans...

Continue Reading